Guangzhou Baiyunshan Pharmaceutical Holdings (SHA:600332, HKG:0874) received approval from China's National Medical Products Administration to make changes to two antibiotics after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.
The pharmaceutical company will be able to change the drug quality standards and packaging of cefoperazone sodium and sulbactam sodium for injection and clindamycin phosphate injection, as well as the latter's formulation process.